scholarly journals Clinical Guideline Highlights for the Hospitalist: 2019 American Thoracic Society/Infectious Disease Society of America Update on Community-Acquired Pneumonia

2020 ◽  
Vol 15 (12) ◽  
pp. 743-745
Author(s):  
Christopher D Jackson ◽  
Desiree C Burroughs-Ray ◽  
Nathan A Summers
Keyword(s):  
Infectious Disease ◽  
Infectious Diseases ◽  
Clinical Guideline ◽  
Target Population ◽  
Community Acquired Pneumonia ◽  
American Thoracic Society ◽  
Funding Source ◽  
Consensus Guidelines ◽  
Release Date ◽  
Immunocompetent Adult

GUIDELINE TITLE: Diagnosis and Treatment of Adults with Community Acquired Pneumonia: An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America RELEASE DATE: October 2019 PRIOR VERSION: 2007 Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults DEVELOPER: American Thoracic Society and Infectious Diseases Society of America FUNDING SOURCE: American Thoracic Society and Infectious Diseases Society of America TARGET POPULATION: Immunocompetent adult patients with community-acquired pneumonia

scholarly journals Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

2007 ◽  
Vol 44 (Supplement_2) ◽  
pp. S27-S72 ◽  
Author(s):  
Lionel A. Mandell ◽  
Richard G. Wunderink ◽  
Antonio Anzueto ◽  
John G. Bartlett ◽  
G. Douglas Campbell ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Community Acquired Pneumonia ◽  
American Thoracic Society ◽  
Consensus Guidelines

scholarly journals Clinical Guideline Highlights for the Hospitalist: Initial Management of Acute Pancreatitis in the Hospitalized Adult

2019 ◽  
Vol 14 (12) ◽  
pp. 764-765
Author(s):  
Ashley Jenkins ◽  
Jordan Shapiro
Keyword(s):  
Acute Pancreatitis ◽  
Clinical Practice ◽  
Clinical Practice Guideline ◽  
Clinical Guideline ◽  
Target Population ◽  
Funding Source ◽  
American Gastroenterological Association ◽  
Release Date ◽  
Initial Management ◽  
Guideline Committee

GUIDELINE TITLE: 2018 American Gastroenterological Association (AGA) Institute Guideline on Initial Management of Acute Pancreatitis RELEASE DATE: March 2018 PRIOR VERSION: Not applicable DEVELOPER: AGA Clinical Practice Guideline Committee FUNDING SOURCE: AGA Institute TARGET POPULATION: Patients within first 48-72 hours of admission with acute pancreatitis (AP)

scholarly journals Clinical Guideline Highlights for the Hospitalist: Anaphylaxis Management in Adults and Children

2021 ◽  
Vol 16 (2) ◽  
pp. 98-99
Author(s):  
Desirée C Burroughs-Ray ◽  
Daniel R Wells ◽  
Mallie M Dennis ◽  
Christopher D Jackson
Keyword(s):  
Systematic Review ◽  
American Academy ◽  
Pediatric Patients ◽  
Clinical Guideline ◽  
Target Population ◽  
Funding Source ◽  
Practice Parameter ◽  
Release Date ◽  
Assessment Development ◽  
Adults And Children

GUIDELINE TITLE: Anaphylaxis—A 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis RELEASE DATE: April 2020 PRIOR VERSION: Anaphylaxis – a 2019 practice parameter and GRADE analysis DEVELOPER: American Academy of Allergy, Asthma & Immunology (AAAAI) and the American College of Allergy, Asthma, and Immunology (ACAAI) FUNDING SOURCE: None TARGET POPULATION: Adult and pediatric patients with anaphylaxis

scholarly journals Clinical Guideline Highlights for the Hospitalist: Therapeutic Monitoring of Vancomycin

2020 ◽  
Vol 15 (12) ◽  
pp. 740-742
Author(s):  
Mark Murphy ◽  
Sonya Tang Girdwood ◽  
Marc H Scheetz
Keyword(s):  
Staphylococcus Aureus ◽  
Infectious Diseases ◽  
Health System ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Clinical Guideline ◽  
Target Population ◽  
Therapeutic Monitoring ◽  
Release Date ◽  
Methicillin Resistant ◽  
American Society

GUIDELINE TITLE: Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists RELEASE DATE: Online: March 19, 2020 PRIOR VERSION: 2009 DEVELOPERS: American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Society of America (IDSA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP) FUNDING SOURCE: ASHP, IDSA, PIDS, SIDP TARGET POPULATION: Adults, children, and neonates treated for documented or presumed methicillin-resistant Staphylococcus aureus infection

Clinical Guideline Highlights for the Hospitalist: Management of Upper Gastrointestinal and Ulcer Bleeding

2021 ◽  
Author(s):  
Duong T Hua ◽  
Charles D Pham
Keyword(s):  
Gastrointestinal Bleeding ◽  
Clinical Guideline ◽  
Upper Gastrointestinal Bleeding ◽  
Target Population ◽  
Adult Patients ◽  
Ulcer Bleeding ◽  
Funding Source ◽  
Release Date ◽  
Practice Parameters ◽  
Upper Gastrointestinal

GUIDELINE TITLE: American College of Gastroenterology: Upper Gastrointestinal and Ulcer Bleeding RELEASE DATE: May 1, 2021 PRIOR VERSION(S): March 1, 2012 DEVELOPER: American College of Gastroenterology Practice Parameters Committee FUNDING SOURCE: American College of Gastroenterology TARGET POPULATION: Adult patients with overt upper gastrointestinal bleeding

scholarly journals Clinical Guideline Highlights for the Hospitalist: Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old

2021 ◽  
Author(s):  
Erin E Shaughnessy ◽  
Samir S Shah
Keyword(s):  
American Academy ◽  
Bacterial Infections ◽  
Clinical Guideline ◽  
Acute Otitis Media ◽  
Target Population ◽  
Funding Source ◽  
Release Date ◽  
American Academy Of Pediatrics ◽  
Healthy Infants ◽  
Simplex Virus

GUIDELINE TITLE: Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old RELEASE DATE: August 1, 2021 PRIOR VERSION(S): n/a DEVELOPER: American Academy of Pediatrics FUNDING SOURCE: American Academy of Pediatrics TARGET POPULATION: Well-appearing, otherwise healthy infants with fever, ages 8 to 60 days, excluding those with prematurity (<37 wk gestation), focal bacterial infections except acute otitis media, high suspicion for herpes simplex virus (vesicles), clinical bronchiolitis

scholarly journals 42. A Pharmacist-Led Intervention to Decrease Anaerobic Coverage for Hospitalized Patients with Community-Acquired Pneumonia

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S44-S45
Author(s):  
Maxx O Enzmann ◽  
Courtney M Pagels ◽  
Emily J Perry ◽  
Justin Jones ◽  
Paul Carson
Keyword(s):  
Infectious Diseases ◽  
Antimicrobial Stewardship ◽  
Community Acquired Pneumonia ◽  
Lung Abscess ◽  
American Thoracic Society ◽  
Hospitalized Patients ◽  
Guidance Document ◽  
Antibiotic Exposure ◽  
Antibiotic Regimen ◽  
Days Of Therapy

Abstract Background Community-acquired pneumonia (CAP) is frequently mis-categorized as aspiration pneumonia, prompting the addition of anaerobic coverage to the antibiotic regimen. In our institution, this usually takes the form of adding metronidazole to ceftriaxone. The 2019 American Thoracic Society and Infectious Diseases Society of America CAP guidelines recommend anaerobic coverage only for hospitalized patients with a suspected lung abscess or empyema. The objective of this study was to determine if a pharmacist-led workflow could increase adherence to the 2019 CAP guideline recommendations by limiting anaerobic coverage to those rare occasions. Methods The hospital antimicrobial stewardship committee approved a pharmacist workflow and guidance document which outlines criteria to evaluate appropriateness of anaerobic coverage for hospitalized patients with CAP and no other indications for antibiotics. If anaerobic coverage is not indicated, the pharmacist submits a standardized message to the treating provider via the electronic medical record, recommending discontinuation of metronidazole. This workflow was implemented on October 3, 2019. Metronidazole days of therapy (DOT) per 1000 patient days in quarters 1 through 4 of 2019 and quarter 1 of 2020 were collected as well as percent acceptance of documented pharmacist interventions from October 3, 2019 until March 31, 2020. Results Between October 3, 2019 and March 31, 2020, a total of 221 interventions were made by pharmacists to discontinue metronidazole in hospitalized CAP patients where anaerobic coverage was not indicated. Out of those 221 interventions, 164 (74%) were accepted by providers and only 57 (26%) were rejected. The DOT per 1000 patient days of metronidazole was assessed for the three quarters prior to our intervention and the two quarters after the intervention. Compared to the three quarters prior, metronidazole DOT per 1000 patient days decreased by 26.6% for the two quarters following implementation of the pharmacist-led intervention (Figure 1). Figure 1: Metronidazole DOT per 1000 patient days from January 1, 2019 through March 31, 2020. Vertical line indicates when pharmacist workflow was implemented. Conclusion A pharmacist antimicrobial stewardship intervention at our institution increased adherence to CAP guidelines and decreased unnecessary antibiotic exposure in hospitalized CAP patients when anaerobic coverage was not indicated. Disclosures All Authors: No reported disclosures

Sign in / Sign up

Export Citation Format

Share Document